Brokerages Set $7.00 Target Price for Immutep Ltd (IMMP)
Shares of Immutep Ltd (NASDAQ:IMMP) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Analysts have set a 1-year consensus price target of $7.00 for the company, according to Zacks. Zacks has also assigned Immutep an industry rank of 98 out of 265 based on the ratings given to related companies.
Separately, Maxim Group reaffirmed a “buy” rating and set a $7.00 price objective on shares of Immutep in a research note on Thursday, November 9th.
ILLEGAL ACTIVITY WARNING: “Brokerages Set $7.00 Target Price for Immutep Ltd (IMMP)” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/06/brokerages-set-7-00-target-price-for-immutep-ltd-immp.html.
Immutep Company Profile
Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immutep Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immutep Ltd and related companies with MarketBeat.com's FREE daily email newsletter.